Latest news with #CookMyoSite
Yahoo
4 days ago
- Business
- Yahoo
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ('Cook MyoSite') to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, 'We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.' Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella's Board of Directors, added, 'Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.' About Cook MyoSite Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection and expansion of human skeletal muscle cells for the treatment of various disorders. In addition to operating several regulated clinical studies, Cook MyoSite provides a range of custom services, including modified cell samples to contract manufacturing arrangements, procurement and processing of muscle cells from specific donor populations, custom media formulations, CMO/CDMO arrangements and QC analytical testing and assay development. Learn more about Cook MyoSite at About Lipella Pharmaceuticals Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking StatementsThis press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals PCG AdvisoryJeff Ramsonjramson@
Business Upturn
4 days ago
- Business
- Business Upturn
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ('Cook MyoSite') to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, 'We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.' Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella's Board of Directors, added, 'Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.' About Cook MyoSite Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection and expansion of human skeletal muscle cells for the treatment of various disorders. In addition to operating several regulated clinical studies, Cook MyoSite provides a range of custom services, including modified cell samples to contract manufacturing arrangements, procurement and processing of muscle cells from specific donor populations, custom media formulations, CMO/CDMO arrangements and QC analytical testing and assay development. Learn more about Cook MyoSite at . About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking Statements This press release includes certain 'forward-looking statements.' All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, including the statistically significant safety and efficacy data presented above for LP-310, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as 'may,' 'will,' 'could,' 'continue,' 'would,' 'should,' 'potential,' 'target,' 'goal,' 'anticipates,' 'intends,' 'plans,' 'seeks,' 'believes,' 'estimates,' 'predicts,' 'expects,' 'projects' and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the current clinical trial for LP-310, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals Inc. [email protected] 1-412-894-1853
Yahoo
30-04-2025
- Business
- Yahoo
Curi Bio and Cook MyoSite Announce Strategic Partnership
Curi Bio and Cook MyoSite Announce Strategic Scientific Collaboration to Advance Translational Human Muscle Disease Models SEATTLE & PITTSBURGH, April 30, 2025--(BUSINESS WIRE)--Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes. Through this collaboration, Curi Bio will integrate its versatile Mantarray 3D tissue engineering platform—compatible with diverse biological models and assays delivering clinically relevant functional outputs—with primary human myoblasts and fibro-adipogenic progenitor cells (FAPs) provided by Cook MyoSite. This integration will produce sophisticated, physiologically relevant tissue models, bridging critical research gaps in conditions such as sarcopenia (age-related muscle atrophy), diabetes, obesity, neuromuscular disorders, and diseases responsive to GLP-1 therapies. "Cook MyoSite's high-quality primary myoblasts and FAPs work wonderfully in our Mantarray system," said Greg Luerman, VP of Research & Partnerships at Curi Bio. "By combining these primary cells into advanced 3D tissue models, we're unlocking novel opportunities to study diseases of muscle, metabolism, and aging that traditional 2D systems and animal models cannot effectively replicate. This collaboration directly benefits our shared customers and accelerates therapeutic advancements for patients." Ryan Pruchnic, Cook MyoSite Managing Vice President, added, "Cook MyoSite brings over two decades of expertise in the field of human primary skeletal muscle cell research. By integrating this expertise and our substantial bank of donor material with Curi Bio's innovative tissue engineering platforms, we're well-positioned to develop powerful tools that will improve preclinical drug screening and disease modeling." The advanced human primary tissue models resulting from this collaboration are commercially available immediately and offer unique capabilities: Translational data not available in traditional animal models or 2D myoblast models. Accelerated drug discovery timelines through early identification of potential efficacy and safety concerns. Enhanced insights into the mechanisms underlying metabolic diseases, including diabetes and obesity, and age-related muscle diseases, fueling innovative therapeutic research. This strategic partnership positions both Curi Bio and Cook MyoSite at the forefront of translational muscle and metabolic science, significantly strengthening the R&D landscape with next-generation platforms that promise to revolutionize the study and treatment of these diseases. About Curi Bio Curi Bio unlocks novel workflows and delivers functional human data to inform biopharmaceutical R&D decision making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis, Curi Bio blends functional and analytical assessments for drug safety, efficacy, and potency. By offering leading global pharmaceutical end users an integrated preclinical platform along with highly predictive human stem cell tissue models to generate clinically-relevant data, Curi Bio is bridging the gap between preclinical R&D and clinical outcomes, accelerating the discovery and development of safer, more effective medicines. For more information, please visit About Cook MyoSite In 2002, Cook MyoSite, Incorporated was formed to guide the Cook Group organization into the expanding world of cellular technologies. Today, Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection, and expansion of human skeletal muscle cells for the treatment of various disorders. Learn more at and View source version on Contacts Curi Bio Media Contact Heejoon ChoiSr. Director, Sales & Marketingheejoon@ Cook MyoSite Media Contact Lindsy BartoleitSenior Manager of Brand & Sign in to access your portfolio
Business Wire
30-04-2025
- Business
- Business Wire
Curi Bio and Cook MyoSite Announce Strategic Partnership
SEATTLE & PITTSBURGH--(BUSINESS WIRE)--Curi Bio, the global leader in human 3D engineered tissue platforms, and Cook MyoSite, a pioneer in the development of skeletal muscle-based therapies, today announced a strategic partnership to develop advanced, predictive human engineered tissue models aimed at addressing muscle-related diseases and metabolic disorders, including obesity and diabetes. This strategic partnership positions both Curi Bio & Cook MyoSite at the forefront of translational muscle & metabolic science, significantly strengthening the R&D landscape with next-generation platforms... Share Through this collaboration, Curi Bio will integrate its versatile Mantarray 3D tissue engineering platform—compatible with diverse biological models and assays delivering clinically relevant functional outputs—with primary human myoblasts and fibro-adipogenic progenitor cells (FAPs) provided by Cook MyoSite. This integration will produce sophisticated, physiologically relevant tissue models, bridging critical research gaps in conditions such as sarcopenia (age-related muscle atrophy), diabetes, obesity, neuromuscular disorders, and diseases responsive to GLP-1 therapies. 'Cook MyoSite's high-quality primary myoblasts and FAPs work wonderfully in our Mantarray system," said Greg Luerman, VP of Research & Partnerships at Curi Bio. "By combining these primary cells into advanced 3D tissue models, we're unlocking novel opportunities to study diseases of muscle, metabolism, and aging that traditional 2D systems and animal models cannot effectively replicate. This collaboration directly benefits our shared customers and accelerates therapeutic advancements for patients.' Ryan Pruchnic, Cook MyoSite Managing Vice President, added, "Cook MyoSite brings over two decades of expertise in the field of human primary skeletal muscle cell research. By integrating this expertise and our substantial bank of donor material with Curi Bio's innovative tissue engineering platforms, we're well-positioned to develop powerful tools that will improve preclinical drug screening and disease modeling." The advanced human primary tissue models resulting from this collaboration are commercially available immediately and offer unique capabilities: Translational data not available in traditional animal models or 2D myoblast models. Accelerated drug discovery timelines through early identification of potential efficacy and safety concerns. Enhanced insights into the mechanisms underlying metabolic diseases, including diabetes and obesity, and age-related muscle diseases, fueling innovative therapeutic research. This strategic partnership positions both Curi Bio and Cook MyoSite at the forefront of translational muscle and metabolic science, significantly strengthening the R&D landscape with next-generation platforms that promise to revolutionize the study and treatment of these diseases. About Curi Bio Curi Bio unlocks novel workflows and delivers functional human data to inform biopharmaceutical R&D decision making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and advanced automated data analysis, Curi Bio blends functional and analytical assessments for drug safety, efficacy, and potency. By offering leading global pharmaceutical end users an integrated preclinical platform along with highly predictive human stem cell tissue models to generate clinically-relevant data, Curi Bio is bridging the gap between preclinical R&D and clinical outcomes, accelerating the discovery and development of safer, more effective medicines. For more information, please visit About Cook MyoSite In 2002, Cook MyoSite, Incorporated was formed to guide the Cook Group organization into the expanding world of cellular technologies. Today, Cook MyoSite is dedicated to the development and subsequent commercialization of technology related to the collection, selection, and expansion of human skeletal muscle cells for the treatment of various disorders. Learn more at and
